(EISAI) A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease

The PI of this project is: Sanjay Asthana, MD

This project is funded by: Eisai Inc.

The term of this project is: January 2018 to January 2021

The number of subjects scanned during this project is: 10